Clinical trial results:
A Post Marketing Surveillance Study to monitor the reactogenicity and safety of Vaxem™Hib when administered according to the prescribing information in Korea.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2014-005203-24
Trial protocol	Outside EU/EEA
Global end of trial date	29 July 2012

Results information

Result version number	v2 (current)
This version publication date	03 June 2016
First version publication date	21 March 2015
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	V37_11

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01404962
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostics
Sponsor organisation address	Via Fiorentina 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 August 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 July 2012
Global end of trial reached?	Yes
Global end of trial date	29 July 2012
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and reactogenicity profile of VaxemHib in Korean children.

Protection of trial subjects:

Study vaccines were not administered to individuals with known hypersensitivity to any component of the vaccines. An oral temperature ≥38.0°C (≥100.4°F) or serious active infection was a reason for delaying vaccination. Standard immunization practices were observed and care was taken to administer the injection intramuscularly. As with all injectable vaccines, appropriate medical treatment and supervision was readily available in case of rare anaphylactic reactions following administration of the study vaccine. Epinephrine 1:1000 and diphenhydramine was available in case of any anaphylactic reactions. Care was taken to ensure that the vaccine is not injected into a blood vessel.

Background therapy:

N/A

Evidence for comparator:

N/A

Actual start date of recruitment	16 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 764
Worldwide total number of subjects	764
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	761
Children (2-11 years)	3
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled from 23 centres in Korea.

Pre-assignment

Screening details:

All enrolled subjects were included in the trial.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	VaxemHib Vaccine

Arm description:

Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.

Arm type	post marketing safety study
Investigational medicinal product name	Haemophilus influenza type b conjugate vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose, pre-filled syringe containing 0.5 mL of liquid vaccine for intramuscular administration.

Number of subjects in period 1	VaxemHib Vaccine
Started	764
Completed	743
Not completed	21
Lost to follow-up	21

Baseline characteristics

Reporting groups	
Reporting group title	VaxemHib Vaccine
Reporting group description:	
Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.	

Reporting group values	VaxemHib Vaccine	Total	
Number of subjects	764	764	
Age categorical Units: Subjects			

Age continuous			
Subjects received 0.5mL of VaxemHib vaccine as part of primary series or as a booster			
Units: days arithmetic mean standard deviation	 162.2 ± 138.9	 -	
Gender categorical			
Subjects received 0.5mL of VaxemHib vaccine as part of primary series or as a booster			
Units: Subjects			
Female	396	396	
Male	368	368	

End points

End points reporting groups

Reporting group title	VaxemHib Vaccine
Reporting group description:	
Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.	
Subject analysis set title	All enrolled Population
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects who have signed an informed consent and undergone procedure(s) for eligibility check for Post Marketing Surveillance	
Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects who receive at least one vaccination and provide some safety data will be considered evaluable for the safety analyses.	

Primary: Number of subjects who reported solicited local and systemic adverse events after vaccination with vaxemHib.

End point title	Number of subjects who reported solicited local and systemic adverse events after vaccination with vaxemHib.[1]
End point description:	
Safety was assessed in terms of number of subjects who reported solicited local and systemic adverse events collected for 7 days after each vaccination.	
End point type	Primary
End point timeframe:	
Days 1 to 7	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: statistical analyses not applicable for this endpoint.

End point values	VaxemHib Vaccine			
Subject group type	Reporting group			
Number of subjects analysed	750			
Units: Number of Subjects				
Any Local	90			
Erythema (N = 741)	8			
Induration (N = 742)	4			
Tenderness (N = 742)	80			
Any Systemic	222			
Change in eating habits (N = 742)	72			
Persistent crying (N = 742)	96			
Irritability (N = 742)	174			
Vomiting (N = 742)	46			
Diarrhea (N = 742)	36			
Any Other	36			
Fever (≥ 38°C)(N = 694)	57			
Temperature (≥ 40°C) (N=694)	1			
Analgesic/Antipyretic medicines used (N = 750)	36			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reporting unsolicited AEs after vaccination with VaxemHib.

End point title	Number of subjects reporting unsolicited AEs after vaccination with VaxemHib.[2]

End point description:

Safety was assessed as the number of subjects who reported unsolicited AEs for 28 days after vaccination with VaxemHib.

End point type	Primary

End point timeframe:

Days 1 to 28

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: statistical analyses not applicable for this endpoint.

End point values	VaxemHib Vaccine			
Subject group type	Reporting group			
Number of subjects analysed	750			
Units: Number of Subjects				
Any AE	360			
At least possibly or probably related AEs	16			
SAEs	6			
At least possibly or probably related SAEs	0			
AEs leading to withdrawal	0			
AEs leading to death	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Day 1 to day 28 after vaccination.	
Adverse event reporting additional description:	
For occurrences table MedDRA 17.1 version was used.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	15.1

Reporting groups	
Reporting group title	VaxemHib Vaccine
Reporting group description:	
Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.	

Serious adverse events	VaxemHib Vaccine		
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 764 (0.79%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			

subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 764 (0.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	VaxemHib Vaccine		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	433 / 764 (56.68%)		
General disorders and administration site conditions			
Crying	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	125 / 764 (16.36%)		
occurrences (all)	145		
Injection Site Pain	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	107 / 764 (14.01%)		
occurrences (all)	119		
Injection Site Erythema	Additional description: For occurrences table MedDra 17.1 version was used		
subjects affected / exposed	41 / 764 (5.37%)		
occurrences (all)	43		
Pyrexia	Additional description: For occurrences table MedDRA 17.1 version was used		
subjects affected / exposed	82 / 764 (10.73%)		
occurrences (all)	102		

Gastrointestinal disorders			
Diarrhoea	Additional description: For occurrences table MedDRA 17.1 version was used		
subjects affected / exposed	62 / 764 (8.12%)		
occurrences (all)	77		
Vomiting	Additional description: For occurrences table MedDRA 17.1 version was used		
subjects affected / exposed	56 / 764 (7.33%)		
occurrences (all)	72		
Respiratory, thoracic and mediastinal disorders			
Cough	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	117 / 764 (15.31%)		
occurrences (all)	133		
Rhinorrhoea	Additional description: For occurrences table MedDRA 17.1 version was used		
subjects affected / exposed	121 / 764 (15.84%)		
occurrences (all)	148		
Psychiatric disorders			
Eating Disorder	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	86 / 764 (11.26%)		
occurrences (all)	99		
Irritability	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	217 / 764 (28.40%)		
occurrences (all)	262		
Infections and infestations			
Bronchitis	Additional description: For occurrences table MedDra 17.1 version was used		
subjects affected / exposed	43 / 764 (5.63%)		
occurrences (all)	56		
Nasopharyngitis	Additional description: For occurrences table MedDRA 17.1 version was used.		
subjects affected / exposed	40 / 764 (5.24%)		
occurrences (all)	54		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported